NCT05985473 Real-time Artificial Intelligence-based Speech Enhancement Methods for Hearing Aid Improvement
| NCT ID | NCT05985473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Deafness Neurosensory |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-03-06 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-03-06 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Individuals with Auditory Neuropathy Spectrum Disorders (ANSD) represent 1-10% of adults with hearing loss. These individuals have little or no benefit from current hearing aids because ANSD is a continuum of hearing impairments due to synaptic or neural dysfunction in the peripheral and central parts of the auditory pathways, which impairs temporal information processing without necessarily affecting auditory sensitivity. There is a need to find ad-hoc denoising methods, based on the expert knowledge of audiologists, to improve the noise comprehension performance of these patients. Implemented denoising methods, based on artificial intelligence, will also greatly benefit more standard hearing loss cases.
Eligibility Criteria
Inclusion Criteria: For all participants: * Age greater than or equal to 18 years, * French mother tongue, * Have an average tonal hearing loss (calculated according to the BIAP method) \< 30 dB HL, on headphones, for each ear, * Be professionally active, not be pre-retired and not be unemployed * Be affiliated with a social security plan, For participants with TSNA: \- Have degraded comprehension in noise (threshold of Intelligibility in Noise \> 3 dB compared to the norm). For controls: \- Have normal comprehension in noise (Intelligibility in Noise threshold ≤ 3 dB from the norm). Exclusion Criteria: For all participants: * Have a conductive or mixed hearing loss, which is when the hearing loss affects both the outer and/or middle ear and the inner ear. * Have an asymmetric hearing loss, i.e. a difference in average hearing loss between the left and right ear greater than 30 dB, * Have sequelae of ear infections and/or a history of ENT disease that permanently affects hearing (vestibular schwannoma, Meniere's disease, sudden or fluctuating deafness, congenital hypoacusis) * Being under guardianship, * Being deprived of liberty by judicial or administrative decision, or being subject to legal protection.
Contact & Investigator
Paul Avan, MD
PRINCIPAL INVESTIGATOR
CEntre de Recherche et d'Innovation en Audiologie Humain
Frequently Asked Questions
Who can join the NCT05985473 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Deafness Neurosensory. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05985473 currently recruiting?
Yes, NCT05985473 is actively recruiting participants. Contact the research team at marta.campi@pasteur.fr for enrollment information.
Where is the NCT05985473 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05985473 clinical trial?
NCT05985473 is sponsored by Institut Pasteur. The principal investigator is Paul Avan, MD at CEntre de Recherche et d'Innovation en Audiologie Humain. The trial plans to enroll 40 participants.